Provided by Tiger Trade Technology Pte. Ltd.

MoonLake Immunotherapeutics

11.41
-0.0600-0.52%
Post-market: 11.570.1600+1.40%19:51 EDT
Volume:1.83M
Turnover:20.66M
Market Cap:971.07M
PE:-2.99
High:11.65
Open:11.64
Low:11.03
Close:11.47
52wk High:23.29
52wk Low:6.56
Shares:85.11M
Float Shares:55.47M
Volume Ratio:1.06
T/O Rate:3.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8139
EPS(LYR):-3.5300
ROE:-67.47%
ROA:-32.44%
PB:2.27
PE(LYR):-3.23

Loading ...

Dec 18, 2024

Major Issues Report

Form 8-K - Current report
Nov 07, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 07, 2024

Major Issues Report

Form 8-K - Current report
Oct 08, 2024

Beneficial Ownership Change

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Sep 11, 2024

Major Issues Report

Form 8-K - Current report
Aug 07, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 07, 2024

Major Issues Report

Form 8-K - Current report
Jun 10, 2024

Major Issues Report

Form 8-K - Current report
Jun 06, 2024

Major Issues Report

Form 8-K - Current report
May 08, 2024

Correspondence

Form CORRESP - Correspondence
May 07, 2024

Major Issues Report

Form 8-K - Current report
May 07, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 07, 2024

[Rev.]Annual Report

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
Mar 11, 2024

Major Issues Report

Form 8-K - Current report
Mar 05, 2024

Beneficial Ownership Change

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
Feb 29, 2024

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 29, 2024

Major Issues Report

Form 8-K - Current report
Feb 26, 2024

Major Issues Report

Form 8-K - Current report
Feb 16, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 15, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]